Apyx Medical (APYX) Projected to Announce Earnings on Thursday

Apyx Medical (NASDAQ:APYX) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Apyx Medical to announce earnings of ($0.06) per share and revenue of $13.1750 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Apyx Medical (NASDAQ:APYX) last posted its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. The company had revenue of $12.49 million during the quarter, compared to the consensus estimate of $10.53 million. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. On average, analysts expect Apyx Medical to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Apyx Medical Stock Performance

NASDAQ APYX opened at $4.28 on Wednesday. Apyx Medical has a fifty-two week low of $1.70 and a fifty-two week high of $5.08. The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80. The firm has a market capitalization of $179.37 million, a P/E ratio of -19.45 and a beta of 1.39. The stock has a 50-day simple moving average of $4.24 and a two-hundred day simple moving average of $3.94.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on APYX. Zacks Research upgraded Apyx Medical to a “hold” rating in a research report on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research note on Wednesday, June 24th. Wall Street Zen lowered shares of Apyx Medical from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. Finally, HC Wainwright began coverage on shares of Apyx Medical in a research note on Monday, July 13th. They issued a “buy” rating and a $7.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Institutional Trading of Apyx Medical

Institutional investors and hedge funds have recently made changes to their positions in the business. Nantahala Capital Management LLC lifted its position in shares of Apyx Medical by 2.5% during the 2nd quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock valued at $7,511,000 after buying an additional 80,000 shares in the last quarter. Osaic Holdings Inc. acquired a new position in Apyx Medical during the second quarter worth $50,000. Vanguard Group Inc. raised its position in Apyx Medical by 3.6% during the third quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock worth $3,272,000 after acquiring an additional 53,175 shares during the period. Franklin Resources Inc. purchased a new position in Apyx Medical during the third quarter valued at $59,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Apyx Medical in the third quarter valued at about $28,000. 55.33% of the stock is currently owned by hedge funds and other institutional investors.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.